Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation
— Organization to Attraction Anticipated Court docket Choice on Particular XIFAXAN® Patents – LAVAL, Quebec, July 28, 2022 /PRNewswire/ — Bausch Health Providers Inc. (NYSE/TSX: BHC), and its gastroenterology company Salix Pharmaceuticals, these days announced the U.S. District Court docket of Delaware issued an Oral Order in the matter of Salix Prescription drugs, Ltd. et al v. Norwich Prescribed drugs, Inc. with regards to the infringement and validity of selected U.S. Patents defending the composition and use of XIFAXAN® (rifaximin)…